THIS IS A REDACTED VERSION OF THE JUDGMENT FOR
PUBLICATION. AN UNREDACTED VERSION HAS BEEN DELIVERED TO THE PARTIES.
CONFIDENTIALITY ORDER AS AT [5] OF JUDGMENT.
IN THE HIGH COURT OF NEW ZEALAND AUCKLAND REGISTRY
I TE KŌTI MATUA O AOTEAROA TĀMAKI MAKAURAU ROHE
CIV-2020-404-000801
[2022] NZHC 1576
BETWEEN PBL SOLUTIONS LIMITED
First Plaintiff
AFT ORPHAN PHARMACEUTICALS LIMITED
Second PlaintiffAND
AFT PHARMACEUTICALS LIMITED
First Defendant
HARTLEY CAMPBELL ATKINSON
Second Defendant
Hearing: 1 July 2022 (teleconference) Appearances:
J Cooper QC, T J Lindsay and C Brownlee for Plaintiffs A Ross QC and Y Lee for Defendants
Judgment:
4 July 2022
REDACTED JUDGMENT OF VENNING J
(Application to adjourn trial)
This judgment was delivered by me on 4 July 2022 at 4.30 pm, pursuant to Rule 11.5 of the High Court Rules.
Registrar/Deputy Registrar
Date……………
Solicitors: Lindsay & Francis, Auckland
Gilbert Walker, Auckland
Counsel:J Cooper QC, Auckland A Ross QC, Auckland
PBL SOLUTIONS LTD v AFT PHARMACEUTICALS LTD [2022] NZHC 1576 [4 July 2022]
Introduction
[1] The first plaintiff PBL Solutions Limited (PBL) and second plaintiff, AFT Orphan Pharmaceuticals Limited (AFTO) have filed an application seeking to adjourn the three week trial scheduled to commence on 31 October 2022 for a year.
[2] Alternatively, they seek an order that the trial is bifurcated so that only issues of liability are determined at the trial, with quantum reserved for a later hearing.
[3] The plaintiffs say that it is in the interests of justice to adjourn the scheduled trial because recent events have resulted in “significant unanticipated uncertainty” as to the quantum of the plaintiffs’ claim. The application is supported by the exhibits to an affidavit from Marcus Peter Dickey, a solicitor in the employ of the plaintiffs’ firm of solicitors.
[4] The defendants, AFT Pharmaceuticals Limited (AFT) and Hartley Atkinson oppose the interlocutory application by the plaintiffs. The defendants’ opposition is supported by an affidavit of Hartley Campbell Atkinson, the Chief Executive Officer and Managing Director of AFT.
Preliminary matter – confidentiality
[5] The parties agree that the annexures to the affidavit of Mr Dickey are to be treated on a confidential basis, as sought in para 5 of Mr Dickey’s affidavit. The affidavit is to be sealed and not to be searched without leave of the Court after hearing from the parties.
Background
[6] This proceeding concerns whether the defendants have breached contractual and fiduciary duties to the plaintiffs by excluding them from opportunities relating to a drug now known as Pascomer as an “orphan drug” for treatment of indications commencing with the ‘orphan’ indication facial angiofibromas (FA) in tuberous sclerosis (TSC).
[7] Orphan drugs are pharmaceutical products used for rare indications, i.e., medical conditions affecting a small proportion of the population. In some jurisdictions, the governing regulatory authority may grant a period of market exclusivity for orphan drugs. Relevantly, for present purposes in the United States of America (US) the term is seven years, and in Europe, 10 years.
[8] Pursuant to a shareholders’ agreement dated on or…
Keep reading for free
Create a free CaseChat account to read PBL Solutions Limited v AFT Pharmaceuticals Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2022] NZHC 1576
- Decision Date
CaseChat Overview and Summary
The court considered the plaintiffs' application for an adjournment or bifurcation of the trial and found that the uncertainty concerning the value of the plaintiffs' claim due to the FDA's decision to grant orphan exclusivity to a competing drug did not warrant an adjournment. The court held that the uncertainty in valuing the potential profits from the commercialisation of Pascomer was always going to be an issue, even from the outset of the proceeding. Furthermore, the court found that an adjournment would affect other litigants and the allocation of the Court's resources, which is a relevant consideration. The court also found that a split trial would not be in the interests of the parties or the Court, as it would result in wasted costs and judicial resources.
In conclusion, the court dismissed the plaintiffs' application for an adjournment of the fixture or bifurcation of the trial. However, the court varied the existing timetable to provide the plaintiffs with further time to address the issue they now face. The plaintiffs were ordered to pay the defendants' costs on a 2B basis for the application and hearing.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.